by Elana Gotkine Specific combinations of antihypertensives are recommended for patients with Bruton’s tyrosine kinase inhibitor (BTKi)-associated hypertension (HTN), according to a study published online Feb. 5 in Blood Advances. Laura Samples, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues examined the optimal treatment of BTKi-associated HTN in a study involving randomly...
